About UsProductsNewsClinical TrialCorporate RelationsResources

Clinical Trial Newsletters

Zuragen™ Clinic Poster

Local Article Example

Q & A

Site List

Educational Incentive Program

CRF Re-order Form

CRF Helpful Hints

Hemodialysis Catheter (Material) Types

Temperature Conversion Chart

For many patients on hemodialysis, a chronic dialysis catheter is used for blood access. Although these catheters are not as long-lasting or as safe as fistulas, they do provide enough blood flow for dialysis in many patients for many months. The greatest risk of these chronic catheters is that they can become infected. When this happens, the patient can become very ill and the catheter may need to be removed. Nationally, the incidence of infection of these dialysis catheters is about 10% per month. In our center, due to the caution and care of our nurses and patients the infection rate is about 1/3 this rate. Still, this represents a significant risk for our patients with chronic catheters.

The [Insert dialysis center name] will be participating in a national clinical trial of a solution (AAT-023) that can be placed into chronic dialysis catheters after each use. This solution is an anticoagulant but also has the ability to kill bacteria and fungus that might contaminate the catheter. A clinical trial protocol has been approved by FDA and the WIRB and will involve randomly assigning patients to receive the usual anticoagulant (heparin) in their catheters after dialysis, or the new solution. We will follow all patients to determine whether the new solution has the ability to keep catheters from clotting and whether it decreases the likelihood of catheter infection. An informational brochure will be distributed shortly regarding the trial. Consult your physician if you have a chronic dialysis catheter and are interested in participating in the trial.